Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists.

Cristina HernándezFernando Gómez-PeraltaOlga Simó-ServatMarta García-RamírezCristina AbreuSara Gómez-RodríguezRafael Simò

Published in: Acta diabetologica (2022)

This pilot study suggests that the increase of circulating EPAC1 after GLP-1RAs treatment could be a useful biomarker to predict clinical GLP1-RAs response.

Keyphrases

wild type